SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 15, 2013--
Exelixis, Inc. (NASDAQ: EXEL) will release its third quarter 2013
financial results on Wednesday, October 30, 2013 after the markets
close. The announcement will be followed by a live webcast at 5:00 p.m.
EDT/ 2:00 p.m. PDT. During the webcast, Exelixis management will discuss
the Company's financial results, financial outlook and development
program and plans for cabozantinib, and also provide a general business
update. The webcast may be accessed in the Event Calendar page under
Investors & Media at www.exelixis.com.
An archived replay of the webcast will be available on the Event
Calendar page under Investors & Media at www.exelixis.com
and via phone until 11:59 p.m. PST on November 30, 2013. Access numbers
for the phone replay are: 888-286-8010 (domestic) and 617-801-6888
(international); the passcode is 62077154.
About Exelixis
Exelixis is a biotechnology company committed to developing small
molecule therapies for the treatment of cancer. Exelixis is focusing its
proprietary resources and development efforts exclusively on COMETRIQ®
(cabozantinib). Exelixis has also established a portfolio of other novel
compounds that it believes have the potential to address serious unmet
medical needs, many of which are being advanced by partners as part of
collaborations. For more information, please visit the company's web
site at www.exelixis.com.
Source: Exelixis, Inc.
Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President,
Investor Relations and Corporate Communications
cbutler@exelixis.com
